EUVIMEDEUVIMED entdecken
Crossref

Improving PROTAC-Mediated Degradation in Mouse Models: BRD9 as a Case Study

Brayden P Strohmier, Jude T Quarshie iD, Rinky Raghuvanshi, Sukhmandeep Kaur, Gabriella G Conjelko, Emily C Dykhuizen iD

ACS Chemical Biology · 21.10.2026

DOI: 10.1021/acschembio.6c00628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 21.10.2026. Verfasst von Brayden P Strohmier und 5 weiteren Autor:innen. Beteiligte Einrichtung: Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana47907, United States. Die Arbeit nennt 38 Literaturangaben. Gefördert von: American Cancer Society, NIGMS NIH HHS, Purdue University Center for Cancer Research.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis-targeting chimeras (PROTACs) have emerged as powerful chemical tools and therapeutics, yet their translation from preclinical models to humans remains inconsistent. Here, we systematically evaluate the activity of BRD9-targeting PROTACs in human and mouse systems to elucidate a key limitation in preclinical studies. Widely used CRBN- and VHL-recruiting degraders, including dBRD9 and VZ185, exhibit markedly reduced potency in mouse cells despite high sequence conservation of BRD9. Mechanistic interrogation reveals that species-specific differences in E3 ligases, particularly the Crbn I391 residue and structural variations in VHL, likely impair productive ternary complex formation. Expression of human CRBN or VHL, or introduction of the CrbnI391V mutation, increases degradation potency in mouse cells. Importantly, in vivo studies demonstrate enhanced BRD9 degradation in CrbnI391V mice using clinically relevant degraders. These findings highlight a critical barrier in PROTAC evaluation and establish humanized E3 ligase models as tools for more accurate assessment of on-target efficacy and toxicity.

Autor:innen und Institutionen

  • Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana47907, United States.

ORCID-Profile: Jude T Quarshie, Emily C Dykhuizen

Förderung

  • American Cancer Society
  • NIGMS NIH HHS
  • Purdue University Center for Cancer Research
  • DOD Prostate Cancer Research Program
  • National Institute of General Medical Sciences
  • Ross-Lynn fellowship from the BMCMP department at Purdue
  • Bilsland Fellowship from the Purdue College of Pharmacy

Zitieren

APA

Strohmier, B. P., Quarshie, J. T., Raghuvanshi, R., Kaur, S., Conjelko, G. G., & Dykhuizen, E. C. (2026). Improving PROTAC-Mediated Degradation in Mouse Models: BRD9 as a Case Study. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00628

Vancouver

Strohmier BP, Quarshie JT, Raghuvanshi R, Kaur S, Conjelko GG, Dykhuizen EC. Improving PROTAC-Mediated Degradation in Mouse Models: BRD9 as a Case Study. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00628

BibTeX
@article{Strohmier2026,
  author = {Strohmier, Brayden P and Quarshie, Jude T and Raghuvanshi, Rinky and Kaur, Sukhmandeep and Conjelko, Gabriella G and Dykhuizen, Emily C},
  title = {Improving PROTAC-Mediated Degradation in Mouse Models: BRD9 as a Case Study},
  journal = {ACS Chemical Biology},
  year = {2026},
  doi = {10.1021/acschembio.6c00628}
}
Kostenlos starten →